百奥泰跌2.01%，成交额4772.14万元，主力资金净流出169.22万元

Core Viewpoint - The stock of Baiotai has experienced fluctuations, with a notable decline of 2.01% on August 28, 2023, despite a year-to-date increase of 55.57% [1][2]. Group 1: Stock Performance - As of August 28, 2023, Baiotai's stock price was 30.15 CNY per share, with a total market capitalization of 12.485 billion CNY [1]. - The stock has seen a recent decline of 9.43% over the last five trading days and a 1.76% decrease over the last 20 days, while it has increased by 13.35% over the last 60 days [1]. Group 2: Financial Metrics - For the first half of 2025, Baiotai reported a revenue of 442 million CNY, reflecting a year-on-year growth of 9.84% [2]. - The company recorded a net profit attributable to shareholders of -125 million CNY, which represents a year-on-year increase of 47.25% [2]. Group 3: Company Overview - Baiotai Biopharmaceutical Co., Ltd. was established on July 28, 2003, and went public on February 21, 2020 [1]. - The company's main business involves the research and production of innovative drugs and biosimilars, with 91.90% of its revenue coming from drug sales [1].